Xianbo Biotech has completed a Series B financing of nearly 400 million yuan.

36Kr learned that Sinobio Therapeutics announced the completion of its Series B financing of nearly 400 million RMB. This round of financing is jointly led by Foton Capital, CBP Capital and Pudong Venture Capital, with follow-on investments from Zhangke Herun, Yuanhe Holdings, and additional investment from existing shareholder Youshan Capital. The raised funds will be mainly used to accelerate the confirmatory clinical research of SNC103, the core pipeline of universal CAR-NK, and promote the registrational clinical development of SNC116, the in vivo CAR-T platform.